Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional Experience by Aaron Wagner et al.
Research Article
Outcomes and Control Rates for I-125 Plaque Brachytherapy for
Uveal Melanoma: A Community-Based Institutional Experience
Aaron Wagner,
1 Andy Chen,
1 Taylor Cook,
2 David Faber,
3
Kirk Winward,
4 and William Sause
2
1 Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA
2Department of Radiation Oncology, Intermountain Medical Center, 5131 Cottonwood Street, Murray, UT 84107, USA
3R o c k yM o u n t a i nR e t i n aA s s o c i a t e s ,M u r r a y ,U T8 4 1 0 7 ,U S A
4Retina Associates of Utah, Murray, UT 84107, USA
Correspondence should be addressed to William Sause; william.sause@imail.org
Received 31 December 2013; Accepted 11 February 2014; Published 9 March 2014
Academic Editors: M. N. Burnier Jr., M. Nakazawa, and H. Quiroz-Mercado
Copyright © 2014 Aaron Wagner et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose. To evaluate our community-based institutional experience with plaque brachytherapy for uveal melanomas with a focus
onlocalcontrolrates,factorsimpactingdiseaseprogression,anddosimetricparametersimpactingtreatmenttoxicity.Methods and
Materials. Our institution was retrospectively reviewed from 1996 to 2011; all patients who underwent plaque brachytherapy for
uveal melanoma were included. Follow-up data were collected regarding local control, distant metastases, and side effects from
treatment. Analysis was performed on factors impacting treatment outcomes and treatment toxicity. Results.At o t a lo f1 0 7p a t i e n t s
underwent plaque brachytherapy, of which 88 had follow-up data available. Local control at 10 years was 94%. Freedom from
progression (FFP) and overall survival at 10 years were 83% and 79%, respectively. On univariate analysis, there were no tumor
or dosimetric treatment characteristics that were found to have a prognostic impact on FFP. Brachytherapy treatment was well
tolerated, with clinically useful vision (>20/200) maintained in 64% of patients. Statistically significant dosimetric relationships
were established with cataract, glaucoma, and retinopathy development (greatest 𝑃 = 0.05). Conclusions.T r e a t m e n tw i t hp l a q u e
brachytherapy demonstrates excellent outcomes in a community-based setting. It is well tolerated and should remain a standard of
care for COMS medium sized tumors.
1. Introduction
Uveal melanoma is an uncommon cancer, with age-adjusted
incidence rates of 4.3 new cases per million [1]. Mortality
however is not rare, with metastases present in up to 20–
39% of patients at 20 years, and tumor related death ranging
from 17–20% at 20 years [2]. There have been multiple inves-
tigations into appropriate treatment options, and current
acceptedstandardsrangefromobservationtoenucleation,all
dependent on the size and characteristics of the tumor [3–5].
Brachytherapy is frequently utilized for medium sized
tumors(apicalheight 3–10mm andbasaldiameter 5–16mm)
a n dh a sb e e ns h o w nt ob ee q u i v a l e n tt oe n u c l e a t i o nf o r
tumors in this category [3]. Treatment delivery is neverthe-
less quite complex, and it has been recommended to only
undertake this treatment approach at medical centers with
theappropriateexpertise[6].Accordingly,recommendations
have been made by the American Brachytherapy Society
regarding appropriate treatment delivery and planning [6].
While the efficacy of plaque brachytherapy has been
well established in large institutional practices that are well
versed in its implementation [7–9], smaller institutional
and community-based results are not as readily available.
In addition, while the long term outcomes from plaque
brachytherapy have been well established [3, 8–10], the
literature does not have very well-documented local control
r a t e sa tl o n gt e r mf o l l o w - u p[ 11] to characterize the time at
which failures occur. Lastly, comparisons of dosimetric and
treatment planning parameters to both treatment toxicity as
well as outcomes are not as well recognized, being limited to
as e l e c tf e ws t u d i e s[ 8, 12–15].
The purpose of this study was to evaluate our institu-
tional community-based practice of brachytherapy for uveal
melanomas. This included looking at survival rates, local
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controlandmetastaticrates,andtherequirementsforsalvage
treatment.Inaddition,furtherinvestigationswereperformed
to evaluate the factors which predicted progression, as well
as dosimetric and tumor factors which predicted ocular
complications.
2. Methods and Materials
Plaque brachytherapy has been utilized for uveal melanomas
at our institution since 1996 and has been performed in
a community-based setting. Institutional review board and
ethics committeeapprovalwas obtained,andpatientstreated
between 1996 and 2011 were retrospectively reviewed, and
all patients who underwent plaque brachytherapy for uveal
melanoma were included. Data was collected regarding
patient demographic data, tumor characteristics, and treat-
ment characteristics. Patients were followed with the treating
ophthalmologist,andfollow-updatawerecollectedregarding
local tumor control, salvage treatment requirements, treat-
ment side effects, occurrence of metastases, and survival
status. Tumor characteristics were classified according to
the COMS classification, with medium sized tumors having
a height of 2.5–10mm and diameter of 5–16mm, large
tumors a height of >10mm or diameter >16mm, and small
tumorsheightsof<2.5mmandnotmeetingrequirementsfor
mediumorlargesizetumors.AJCCstagewasassignedperthe
AJCC 7th edition staging.
Patients were diagnosed by fundoscopic exam, fluo-
rescein angiography, and B-scan ultrasound examination.
Tumorcharacteristicswererecordedincludingtumordimen-
sions, location, and distance from intraocular structures.
Plaque implants were performed in accordance with
American Brachytherapy Society recommendations [6].
Patients were evaluated by one of three ophthalmologists
trained in plaque brachytherapy and our institutional radia-
tiononcologydepartment.Tumorswerelocalizedbyindirect
ophthalmoscopy and occasionally fundoscopic photography
inclinicandtransilluminationatthetimeofsurgery.Plaques
of the COMS type were chosen with an additional tumor
base margin of at least 2mm. Treatment was planned in
accordance with the American Association of Physicists in
Medicine (AAPM) Updated Task Group Number 43 Report.
Dose calculations were performed per the COMS protocol
using the Bebig Plaque Simulator software. The sources were
treated as point sources without corrections for anisotropy,
silastic carrier attenuation, scatter from the gold plaque, or
L-shell fluorescence. Dose points were carried at the tumor
apex, the center of the optic disk, the center of the lens,
the scleral surface, and the macula. Iodine-125 (I-125) was
utilizedinallcases,withaplanneddoseof85Gytothetumor
apex, or to a 5mm depth when tumors were less than 5mm
in height.
Surgery was performed by the referring ophthalmologist
with a radiation oncologist and physicist present. Plaque
position was verified either with a dummy plaque or indirect
ophthalmoscopy with scleral depression. Muscle transposi-
tionwasperformedifnecessitatedbytumorposition.Plaques
were sutured in place and left in place for a time interval as
dictated by source strength and desired dose, before being
removed.
Plannedfollow-upwaswiththetreatingophthalmologist,
with scheduled appointments planned for 3 to 6 months
during the first year, followed by 6 months to annually there-
after.Patientsunderwentrepeatfundoscopicexamination,as
well as yearly B-scan ultrasound evaluation. Yearly hepatic
enzymeevaluationandliverultrasoundasindicatedwerealso
performed.
Statistical analysis was performed using StatsDirect sta-
tistical software (version 2.7.8, Stats Direct Ltd., Altrincham,
UK). Survival was calculated from time of the implant.
Kaplan-Meiercurvesweregeneratedforbothoverallsurvival
and freedom from progression (OS and FFP, resp.), as well
as independently for local control (LC) rates and freedom
from distant metastases. FFP was defined as simultaneous
l o c a lc o n t r o la n dt h ea b s e n c eo fd i s t a n tm e t a s t a s e s .L o c a l
control was evaluated by the treating ophthalmologist with
repeat fundoscopic examination, and control was defined as
novisibletumorgrowth.Ifanyfurthersalvagetreatmentwas
performed, such as laser photocoagulation, this was deemed
a failure even in the absence of tumor growth. Univariate
analysiswasperformedbylogrankanalysistoidentifyfactors
impacting FFP. Statistical significance of factors affecting
side effect rates was performed with an unpaired 𝑡-test for
continuous variables and Pearson 𝜒
2 test for categorical
variables. Statistical significance was defined at 𝑃 = 0.05.
3. Results
Between April of 1996 and November of 2011, 107 patients
underwent plaque brachytherapy for uveal melanoma for
which dosimetric data were available. Of these, 88 patients
had data regarding treatment follow-up. Patient charac-
teristics are displayed in Table 1.F o ra l lp a t i e n t s ,8 5 %o f
tumors were in the COMS medium sized category, with the
majority of the others in the small category. The mean largest
diameter was 10.67mm (5.70–18.30mm), the mean height
was 4.49mm (1.60–10.17mm). The mean distance to the
macula was 6.07mm (0–15.73mm), and the mean distance
to the optic disk was 5.93mm (0.01–17.37mm).
I
125 was utilized for all seed implants, and the most
common plaque utilized was the COMS 14 size. The average
number of seeds was 14 (range 5–24). The average treatment
timewas102.11hours,withanaveragedoserateof0.92Gy/hr
to the tumor apex. The average seed activity was 3.2mCi.
The actual delivered treatment dosimetric characteristics are
displayed in Table 2.
Patient OS and FFP is displayed in Figure 1.M e d i a n
follow-up for the 88 evaluable patients was 48.9 months
(range 1–156 months). The five- and ten-year OS for our
patient population was 90% and 79%, respectively (95% C.I.
79–95%, and 64–88%, resp.). The five- and ten-year FFP was
88% and 83%, respectively (95% C.I. 73–95%, and 62–93%,
resp.).Thelocalcontrolandmetastasisfreeratesaredisplayed
inFigure 2.Five-andten-yearlocalcontrolrateswere94%at
both time points (95% C.I. 82–98% and 82–98%, resp.), and
metastasis free rates were 95 and 89% at five and ten yearsISRN Ophthalmology 3
Table 1: Patient and tumor characteristics.
All treated
patients
Patients with available
F/U
Number of Patients 107 88
Age at diagnosis (yr)
Median 65 65
Range 22–93 22–93
Sex
Male 60 (56%) 48 (55%)
Female 47 (44%) 40 (45%)
Laterality
Left 56 (52%) 47 (53%)
Right 51 (48%) 41 (47%)
Preexisting Conditions
Hypertension 50 (47%) 40 (45%)
CVS Disease 16 (15%) 12 (14%)
Diabetes 15 (14%) 10 (11%)
Smoking History 17 (16%) 18 (20%)
COMS Classification
Small 13 (12%) 12 (14%)
Medium 91 (85%) 74 (84%)
Large 3( 3 % ) 2( 2 % )
Stage
T1a 39 (36%) 32 (36%)
T1b 1 (1%) 1 (1%)
T2a 43 (40%) 38 (43%)
T2b 5 (5%) 5 (6%)
T3a 15 (14%) 9 (10%)
T3b 3( 3 % ) 3( 3 % )
T4a 1 (1%) 0 (0%)
T4b 0 (0%) 0 (0%)
Equatorial position
Anterior 8 (7%) 7 (8%)
Posterior 70 (65%) 58 (66%)
Spanning 25 (23%) 20 (23%)
Unknown 4 (4%) 3 (3%)
F/U: follow-up; COMS: collaborative ocular melanoma study; CVS: cardio-
vascular.
Table 2: Delivered dosimetric parameters.
Median dose (Gy) Range (Gy)
Tumor apex 85.90 83.72–147.20
Inner sclera 248.95 99.99–1132.30
Opposite retina 6.44 2.84–23.30
Macula 46.51 8.17–174.47
Optic disc 39.78 8.18–238.70
Lens center 13.31 4.53–112.10
Gy: gray.
(95% C.I. 79–99% and 67–97%, resp.). Local failure was seen
in only three patients, one of whom underwent enucleation,
and two patients underwent transpupillary thermotherapy.
Fifteenpatientsalsounderwentlaserphotocoagulationatthe
time of plaque implant.
A univariate analysis was then performed for factors
affecting FFP. Factors evaluated included patient age, sex,
dose to the tumor apex, and tumor characteristics including
COMS classification, AJCC stage, tumor location by equato-
rial position, involvement of the ciliary body, tumor height,
and plaque margin on the tumor. Dose was dichotomized
bothtodosestotheapexof<or≥85Gyaswellas<or≥90Gy.
Results are displayed in Table 3. There were no statistically
significant variables impacting FFP seen. With no significant
variables on univariate analysis, a multivariate analysis was
not performed.
Overall, treatment was well tolerated. Cataract formation
a n dr a d i a t i o nr e t i n o p a t h yw e r es e e ni n2 5 %a n d2 2 %o f
patients, respectively. Glaucoma was noted after treatment in
6% of patients. Optic neuropathy was seen in 3% of patients.
Other complications noted included mild/transient diplopia,
retinal detachment/hemorrhage, and conjunctival irritation.
Decreased visual acuity was the most common functional
changeseen,with64%ofpatientsmaintainingbestcorrected
vision of 20/200 or better. Results are displayed in Table 4.
The impact of dosimetric variables and select tumor
characteristicsontreatmentsideeffectswastheninvestigated.
Variables were chosen in accordance to logical associations,
andablanketanalysisofallknownfactorswasnotperformed.
A statistically significant correlation between lens dose and
cataract formation was seen (𝑃 = 0.05). In addition,
correlations between lens dose and glaucoma formation, as
well as both tumor apex and 5mm depth dose to radiation
retinopathy, were also noted (𝑃 = 0.04, 𝑃 = 0.01,a n d𝑃=
0.04, resp.). No other dosimetric variables were statistically
noted to have an impact on the incidence of side effects to
treatment. Results are displayed in Table 5.
4. Discussion
The results of the COMS [3, 16] studies have well demon-
strated that plaque brachytherapy is an acceptable treatment
modality for medium sized tumors. The 5-year OS was 82%
and 81%, and rates of distant metastases 91% and 89% for
the patients receiving plaque brachytherapy and enucleation,
respectively, with no statistical difference between treatment
modality [16]. Longer term follow-up demonstrated that
there continued to be no survival difference between these
two treatment modalities [3], and in light of lower treatment
morbidity plaque brachytherapy has become the predomi-
nant treatment modality [17].
While the COMS study has validated the implemen-
tation of plaque brachytherapy for medium sized tumors,
the process is complex and special considerations must be
undertaken in a multidisciplinary approach [6]. As such
it is important to verify that the results obtained by the
COMS study can be translated into clinical practice and that
results are not limited to a few large institutions. Many of
the largest studies to date have come from select institutions4 ISRN Ophthalmology
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Figure 1: (a) Overall survival of patient population. (b) Freedom from progression from either local disease or distant metastases.
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Figure 2: (a) Local control. (b) Freedom from metastatic disease.
[7–10, 15, 18–21], and reports from other clinical practices are
much more limited.
The results of our study also demonstrate excellent out-
comes for the utilization of plaque brachytherapy. Our 5-
and 10-year OS rates were 90 and 79%, respectively. At the
same time intervals, 88% and 83% remained free from either
local failures or distant metastases. These results are similar
to the COMS report [3], where 10-year OS for both groups
cumulatively was 65%, and 10-year survival in the absence
of metastatic disease was 83%, demonstrating that at least
equivalent results can be obtained in a community practice
based setting.
Our results demonstrated local control which plateaued
after 3 years, with long term local control being 94%. These
results compare favorable to the COMS study, where 5-
year local control rates were reported as 89.7% [22]. Several
institutions have shown similar control rates, ranging from
81 to 93% [12, 15, 21, 23], and, in a study by Leonard et
al. [11], a literature review was performed where the 5-year
local control average was thought to be 88.1% for I-125
plaques. However, it was noted in the same study that long
term local control has not been as well established, with
rates confined almost entirely to select few studies [7, 18, 19,
24]. While a limited number of patients were evaluable for
long term follow-up in our study (for LC only 11 patients
at 10 years), the 10-year local control rate was 94%, with
only 3 patients having experienced a true local failure. In
addition, these failures all occurred within the first 3 years
of therapy. Nevertheless, other studies have continued to
show late recurrences after 5 years [18], and our study also
demonstrated an even distribution of metastases over the
time period evaluated, indicating the need for continued
follow-up and close monitoring long term.
I no u rs t u d y ,n os i g n i fi c a n tp r o g n o s t i cf a c t o r sw e r es e e n
to impact FFP rates. This includes patient demographic
variables, tumor characteristics, plaque margin, and tumor
apex dose. In contrast, in a report by Leonard et al. [11],
multiple factors including gender and apical height were
predictiveoflocalfailureonunivariateanalysis.Similarly,ina
reportbyJensenetal.[12],tumordiameter,tumorheight,andISRN Ophthalmology 5
Table 3: Univariate analysis on factors impacting.
HR 95% C.I.
Age
<60 Referent
≥60 2.56 0.58–11.26
Sex
Male Referent
Female 2.00 0.44–9.06
COMS classification
Small 0.84 0.11–6.13
Medium/large Referent
T-stage
1 0.68 0.13–3.69
2 Referent
3 1.11 0.16–7.75
4 2.71 0.16–7.73
Equatorial position
Anterior 1.07 0.21–5.46
Spanning 1.66 0.11–25.64
Posterior Referent
Ciliary body involvement
Not involved Referent
Involved 1.89 0.12–28.75
Tumor height
<5mm Referent
≥5mm 1.04 0.23–4.67
Plaque margin
<3.5mm 2.79 26.08–0.30
≥3.5mm Referent
Apex dose
<85Gy 0.33 0.03–3.32
≥85Gy Referent
<90Gy Referent
≥90Gy 2.13 0.46–9.76
FFP: freedom from progression; COMS: collaborative ocular melanoma
study.
Table 4: Side effects from treatment.
Side effects
Pts with evaluable f/u 88
Clinically useful vision 56 (64%)
Cataracts 21 (24%)
Radiation retinopathy 19 (22%)
Optic neuropathy 3 (3%)
Glaucoma 5 (6%)
tumor apex dose, as well as other factors, were predictive of
either local failure or distant metastasis. In the COMS study
[3], tumor diameter, apical height, and equatorial position
were all predictive of development of distant metastasis.
While these results certainly contrast with our study, the lack
of prognostic impact can be explained fairly readily by the
low instances of either local failures or distant metastases,
Table 5: Analysis of factors predicting for treatment side effects.
Absent
(mean)
Present
(mean)
𝑃 value
Cataracts
Lens dose (Gy) 14.67 24.64 0.05
Glaucoma
Lens dose (Gy) 17.12 32.11 0.04
Retinopathy
5mmdepthdose(Gy) 78.48 108.6 0.01
Inner dclera dose (Gy) 280.65 333 0.14
Tumor size (mm) 10.47 10.52 0.93
Tumor height (mm) 4.26 4.68 0.40
Dose apex (Gy) 91.19 96.99 0.04
Optic neuropathy
Macula dose 62.51 95.7 0.22
Optic disk dose 47.06 48.83 0.93
Clinically useful vision
Tumor size (mm) 11.22 10.28 0.10
5mmdepthdose(Gy) 98.34 83.48 0.15
Optic disk dose (Gy) 55.25 44.81 0.25
Inner sclera dose (Gy) 343.67 280.75 0.10
Macula dose (Gy) 75.49 60.31 0.20
and these numbers were likely not adequate to demonstrate
any statistical significance regarding these outcomes in the
absence of higher patient numbers.
The availability of studies evaluating a dosimetric impact
on treatment toxicity is relatively limited. Jensen et al. [12]
performed evaluations regarding both total doses and dose
rates on both treatment outcomes and toxicity. They found
associationsinvisualacuityorblindnesswithtotaldosesand
dose rates to the macula, optic disk, and lens. G¨ und¨ uz et al.
[8]onunivariateanalysisfoundmaculopathytobeassociated
with apex dose rate, and papillopathy to be associated with
apex dose rate and optic disk dose. Jones et al. [13]n o t e d
association between dose rates to the macula and visual
decline after treatment. Stack et al. [14]n o t e dr e l a t i o n s h i p s
between dose and development of maculopathy and cataract
formation.
The results of our study also demonstrated causal rela-
tionships between total dose to ocular structures and treat-
ment toxicity. A statistical increase in cataract formation
was noted with increased mean lens dose (𝑃 = 0.05).
This is not surprising, as the association between lens dose
and cataract formation is well known [25, 26]. In addition,
a relationship between lens dose and glaucoma formation
was also noted (𝑃 = 0.04). While the rates of radiation
induced glaucoma in our study were relatively low, 6%,
neovascularization was noted in almost 50% of the cases,
and a causal relationship of neovascularization caused by
radiation induced ischemia, and subsequent neovascular
glaucomahasbeennoted[27]. Lastly, an association between
both 5mm depth dose and tumor apex dose to retinopathy
was also observed (𝑃 = 0.01 and 𝑃 = 0.04,r e s p . ) ,6 ISRN Ophthalmology
indicating a correlation between increased prescription dose
andthedevelopmentofretinopathy.Overall,theseresultsare
consistent with institutional reports of the dose dependence
of treatmentcomplications, and while the exact relationships
vary to some degree between our study and other published
reports, it does seem to indicate that causal relationships do
exist.
At the same time, while dose-dependent toxicities may
be established, this should not necessarily change clinical
practice. Tumor control is still the primary objective, and a
reduced tumor dose or dose rate to improve toxicity might
result in poor control. While the results of our study do
not demonstrate any impact on FFP with dose thresholds
of 85Gy or 90Gy, other dose effects have been noted. In
the aforementioned study by Jensen et al. [12], decreased
t o t a ld o s et ot h et u m o ra p e xo f<100Gy and dose rates of
<90cGy/hr, while both associated with improved toxicity,
were also associated with increased rates of metastases, and
other studies have also demonstrated similar associations
[8, 15] .W h i l et h ea c t u a ld o s ea n dr a t et h r e s h o l d sv a r yi nt h e
literature, a threshold does seem to exist. As a result, while
dose-dependent toxicity relationships are present, clinical
benefitsarelikelyintherealmofimprovedpatientcounseling
rather than tailored treatment.
Limitations to our study certainly exist. Not all patients
had follow-up data available, especially with longer follow-
up approaching 10 years, as indicated by the lower number
of patients for whom primary outcomes and treatment
complications were evaluable. In addition, with low rates of
recurrences and metastases, many more patients would be
required to fully establish relationships between dosimetric
andtumorcharacteristicsandtreatmentoutcomes.Thissame
critique applies to evaluating causal factors for treatment
complications. In addition, it is a retrospective study, and
limitations such as loss to follow-up, completeness of treat-
ment records, record uniformity, and variations in follow-up
monitoring all apply. Nevertheless, it still serves as a valuable
marker of clinical practice in the modern era.
In conclusion, this series continues to demonstrate
excellent and reproducible clinical outcomes for plaque
brachytherapy for uveal melanomas, with satisfactory long
term control. Local recurrences are quite rare, and treatment
is well tolerated with decreases in visual acuity being the
most common effect of treatment. Relationships appear to
exist between treatment toxicity and doses to intraocular
structures. Further evaluation would be warranted to fully
evaluate these relationships.
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